Stockscreener 앱 받기
14.99
6.24%
0.88
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 4.2%Time to Buy? - MarketBeat
State Street Corp Boosts Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Long Term Trading Analysis for (ARQT) - Stock Traders Daily
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 9.4%What's Next? - MarketBeat
Franklin Resources Inc. Decreases Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics Soars on Zoryve Success and Bullish Analyst Ratings - Nasdaq
Investors Purchase Large Volume of Call Options on Arcutis Biotherapeutics (NASDAQ:ARQT) - MarketBeat
Arcutis stock soars to 52-week high, hits $13.56 amid robust gains - Investing.com Canada
Arcutis Biotherapeutics (NASDAQ:ARQT) Hits New 52-Week HighHere's Why - MarketBeat
FDA Receives sNDA for Roflumilast Cream Treatment of Children with Atopic Dermatitis - MD Magazine
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Sees Large Decrease in Short Interest - MarketBeat
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis - The Manila Times
Arcutis Submits FDA Application for ZORYVE Cream After Promising Child Eczema Trial Results - StockTitan
Arcutis stock soars to 52-week high, hits $13.56 amid robust gains By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 4.8%Here's Why - MarketBeat
Point72 Asset Management L.P. Invests $2.27 Million in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Position Lessened by Jacobs Levy Equity Management Inc. - MarketBeat
How to Take Advantage of moves in (ARQT) - Stock Traders Daily
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
Arcutis Biotherapeutics Awards Equity Grants to New Employees Under Inducement Plan - StockTitan
Arcutis Biotherapeutics CEO Todd Watanabe buys $21,250 in stock - Investing.com India
Arcutis announces key executive promotions By Investing.com - Investing.com South Africa
Arcutis announces key executive promotions - Investing.com India
Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - MSN
Insider Sell Alert: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus.com
Arcutis Biotherapeutics director sells $125,132 in stock - Investing.com India
Arcutis Biotherapeutics CEO Todd Watanabe buys $21,250 in stock By Investing.com - Investing.com Canada
Arcutis Biotherapeutics director sells $125,132 in stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics exec buys $7,766 in stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics exec buys $7,766 in stock - Investing.com
Arcutis Announces Promotions on Executive Management Team - The Manila Times
Arcutis Biotherapeutics Strengthens Leadership Team Following ZORYVE Portfolio Success - StockTitan
Short Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Drops By 9.9% - MarketBeat
Algert Global LLC Increases Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics Submits Roflumilast Cream 0.15% Supplemental NDA to US FDA for Eczema Treatment - Marketscreener.com
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Position Lifted by Suvretta Capital Management LLC - MarketBeat
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect? - MSN
(ARQT) Investment Analysis - Stock Traders Daily
Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy? - Zacks Investment Research
Rubric Capital Management LP Grows Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
There's Reason For Concern Over Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Massive 32% Price Jump - Simply Wall St
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Position Increased by Jennison Associates LLC - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average - MSN
Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now - MSN
Arcutis Biotherapeutics SVP sells $17,190 in stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics SVP sells $17,190 in stock - Investing.com India
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates - MSN
2.88%
2.65%
자본화:
|
볼륨(24시간):